LNC
TCRT icon

Lincoln National Corp’s Alaunos Therapeutics TCRT Stock Holding History

Lincoln National Corp’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-250
Closed -$99K – 908
2021
Q2 		$99K Buy
+250
New +$117K ﹤0.01% 842

Other funds holding TCRT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Lincoln National Corp's TCRT Position: Q3 2021 in Review

Lincoln National Corp sold out of Alaunos Therapeutics (TCRT) in Q3 2021, closing a stake of 250 shares — an estimated $99K sold.

Lincoln National Corp first reported a position in TCRT in Q2 2021 and held it in 1 quarter. The position peaked at $99K in Q2 2021. 162 funds tracked by Wall St. Rank hold TCRT as of Q3 2021.

  • Lincoln National Corp reported no remaining Alaunos Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Lincoln National Corp sold 250 Alaunos Therapeutics shares in Q3 2021, an estimated $99K.
  • Lincoln National Corp first reported a position in Alaunos Therapeutics in Q2 2021 and held it in 1 quarter.
  • Lincoln National Corp's Alaunos Therapeutics position peaked at $99K in Q2 2021.
  • 162 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q3 2021.

Based on Lincoln National Corp's 13F filing for Q3 2021, filed 5 Nov 2021.